industry
Healthcare & Life Sciences

Optometry practice sees higher valuation after sell-side readiness transformation​

Key result:
  • Successfully sold company at higher-than-anticipated sale price
Value levers pulled:
  • Sell-side readiness
  • Budgeting and forecasting process improvement
  • Big data analytics
  • Corporate development/M&A execution support

Picture this...

You’re a leading optometry/ophthalmology practice preparing for sale. But you’re nowhere near ready, and you need material preparation assistance and overall analytical transaction and diligence support throughout the process. ​

You turn to Accordion.

We partner with your team to:

  • Take a leadership role in the preparation of materials—assisting with the financial model and projections, developing a comprehensive data room for due diligence, and fielding diligence requests on the fly.
  • Help you develop your annual budget to be presented and approved by new ownership post-sale transfer from middle market to large-cap private equity firm.
  • Provide additional FP&A and analytical support by developing user friendly and quick-to-update models, including:
    • A “what’s best” office model to evaluate performance across 400 offices with a financial model for leadership decision-making.
    • A realization model to track and analyze revenue changes by service and payer.
    • An AR Aging and DSO model for monitoring receivables and payment collection times.

Your value is enhanced.

You successfully sell your company at a higher than anticipated valuation. Your improvements in the calculation of historical wage accruals and expenses allow for a significant add-back in the QoE, which lets you sell at an increased sale price. Going forward, you have the models necessary to enable additional insight and improve overall decision-making.

Enhanced value:

You reap multiple benefits, including:

  • One-time inventory reduction of $4M and a $400K recurring benefit
  • Increased throughput by 11%, creating a $15M revenue lift
  • Productivity gain across all product lines drive recurring benefit of $3M
  • $5.2M EBITDA improvement as a recurring benefit